123 related articles for article (PubMed ID: 15324480)
1. Oral delivery of spray dried PLGA/amifostine nanoparticles.
Pamujula S; Graves RA; Freeman T; Srinivasan V; Bostanian LA; Kishore V; Mandal TK
J Pharm Pharmacol; 2004 Sep; 56(9):1119-25. PubMed ID: 15324480
[TBL] [Abstract][Full Text] [Related]
2. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers.
Ungaro F; d'Angelo I; Coletta C; d'Emmanuele di Villa Bianca R; Sorrentino R; Perfetto B; Tufano MA; Miro A; La Rotonda MI; Quaglia F
J Control Release; 2012 Jan; 157(1):149-59. PubMed ID: 21864595
[TBL] [Abstract][Full Text] [Related]
3. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.
Italia JL; Bhatt DK; Bhardwaj V; Tikoo K; Kumar MN
J Control Release; 2007 Jun; 119(2):197-206. PubMed ID: 17399839
[TBL] [Abstract][Full Text] [Related]
4. Spray-drying preparation of microparticles containing cationic PLGA nanospheres as gene carriers for avoiding aggregation of nanospheres.
Takashima Y; Saito R; Nakajima A; Oda M; Kimura A; Kanazawa T; Okada H
Int J Pharm; 2007 Oct; 343(1-2):262-9. PubMed ID: 17628365
[TBL] [Abstract][Full Text] [Related]
5. Radioprotection in mice following oral delivery of amifostine nanoparticles.
Pamujula S; Kishore V; Rider B; Fermin CD; Graves RA; Agrawal KC; Mandal TK
Int J Radiat Biol; 2005 Mar; 81(3):251-7. PubMed ID: 16019934
[TBL] [Abstract][Full Text] [Related]
6. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.
Mittal G; Sahana DK; Bhardwaj V; Ravi Kumar MN
J Control Release; 2007 May; 119(1):77-85. PubMed ID: 17349712
[TBL] [Abstract][Full Text] [Related]
7. Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment.
Westedt U; Kalinowski M; Wittmar M; Merdan T; Unger F; Fuchs J; Schäller S; Bakowsky U; Kissel T
J Control Release; 2007 May; 119(1):41-51. PubMed ID: 17346845
[TBL] [Abstract][Full Text] [Related]
8. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy.
Mukerjee A; Vishwanatha JK
Anticancer Res; 2009 Oct; 29(10):3867-75. PubMed ID: 19846921
[TBL] [Abstract][Full Text] [Related]
9. PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies.
Gavini E; Chetoni P; Cossu M; Alvarez MG; Saettone MF; Giunchedi P
Eur J Pharm Biopharm; 2004 Mar; 57(2):207-12. PubMed ID: 15018976
[TBL] [Abstract][Full Text] [Related]
10. Preparation of amifostine polylactide-co-glycolide microspheres and its irradiation protective to mouse through oral administration.
Lu TL; Sun WG; Zhao W; Chen T
Drug Dev Ind Pharm; 2011 Dec; 37(12):1473-80. PubMed ID: 21721846
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery.
Chong CS; Cao M; Wong WW; Fischer KP; Addison WR; Kwon GS; Tyrrell DL; Samuel J
J Control Release; 2005 Jan; 102(1):85-99. PubMed ID: 15653136
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers.
Beletsi A; Panagi Z; Avgoustakis K
Int J Pharm; 2005 Jul; 298(1):233-41. PubMed ID: 15936907
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis.
Kumar G; Sharma S; Shafiq N; Pandhi P; Khuller GK; Malhotra S
Drug Deliv; 2011 Jan; 18(1):65-73. PubMed ID: 20735202
[TBL] [Abstract][Full Text] [Related]
14. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells.
Elamanchili P; Diwan M; Cao M; Samuel J
Vaccine; 2004 Jun; 22(19):2406-12. PubMed ID: 15193402
[TBL] [Abstract][Full Text] [Related]
15. PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery.
Csaba N; Sánchez A; Alonso MJ
J Control Release; 2006 Jun; 113(2):164-72. PubMed ID: 16759732
[TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of novel biodegradable microspheres based on poly(d,l-lactide-co-glycolide) and poly(epsilon-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: in vitro and in vivo studies.
Mundargi RC; Srirangarajan S; Agnihotri SA; Patil SA; Ravindra S; Setty SB; Aminabhavi TM
J Control Release; 2007 May; 119(1):59-68. PubMed ID: 17331611
[TBL] [Abstract][Full Text] [Related]
17. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution.
Mainardes RM; Evangelista RC
Int J Pharm; 2005 Feb; 290(1-2):137-44. PubMed ID: 15664139
[TBL] [Abstract][Full Text] [Related]
18. Preparation and in vitro characterization of amifostine biodegradable microcapsules.
Pamujula S; Graves RA; Kishore V; Mandal TK
Eur J Pharm Biopharm; 2004 Mar; 57(2):213-8. PubMed ID: 15018977
[TBL] [Abstract][Full Text] [Related]
19. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon.
Krishnamachari Y; Madan P; Lin S
Int J Pharm; 2007 Jun; 338(1-2):238-47. PubMed ID: 17368982
[TBL] [Abstract][Full Text] [Related]
20. Improved bioavailability of orally administered mifepristone from PLGA nanoparticles.
He W; Horn SW; Hussain MD
Int J Pharm; 2007 Apr; 334(1-2):173-8. PubMed ID: 17101249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
